Navigation Links
Isis Pharmaceuticals to receive $1.4 million from Alnylam
Date:8/28/2012

CARLSBAD, Calif., Aug. 28, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will receive $1.4 million from Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) as its portion of the upfront fees in Alnylam's recently announced collaboration in the field of agriculture.  In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments.  This transaction further emphasizes the value of Isis' innovation and the leadership role Isis has played in the field of RNA-based technology.

Isis is the leading company in RNA-based technology and owns or controls more than 1,500 issued patents.  As such, Isis holds patents for numerous applications of antisense technology, including RNAi, and for novel targets, such as microRNAs being developed by Regulus, which is co-owned by Isis and Alnylam.  In 2004, Isis and Alnylam entered into a strategic relationship in which Alnylam obtained an exclusive license to Isis' intellectual property for double-stranded oligonucleotide therapeutics that mediate RNAi.  In return, Isis received an upfront payment and financial participation in future transactions supported by Isis' patents.

"Our innovations and discoveries related to RNA-based technologies have resulted in a broad and valuable patent estate.  Our business strategy is focused on maximizing the value of these innovations by providing partners access to our technology for uses that are outside of our area of focus.  The benefit of this strategy is evident in the success of the strategic relationships we establish, such as the one we have with Alnylam," said B. Lynne Parshall, Chief Operating Officer and CFO of Isis.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director
2. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
3. Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
4. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
5. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
6. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
7. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
8. Actinium Pharmaceuticals Strengthens Management Team
9. Alexza Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference
10. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
11. Access Pharmaceuticals To Host Second Quarter Investor Call on Thursday, August 23, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... Scientists ... approach to build nearly complete genomes by combining high-throughput DNA sequencing with genome ... important for their association with human disease, but previously difficult to detect. The ...
(Date:6/29/2015)... ... ... USA Today reported on June 18th the overdose death rate has ... rest of the nation’s growing overdose death rates in 26 other states the U.S. ... stop the increasing overdose trend from continuing: , , Encourage and ...
(Date:6/29/2015)... ... June 29, 2015 , ... New research released ... than 10 percent of U.S. state and local governments have implemented Next Generation ... deadline for NG9-1-1. , “Mobile phones have surpassed land lines as the ...
(Date:6/29/2015)... Detroit, MI (PRWEB) , ... June 29, 2015 , ... ... offer Kybella™ injection to clients for the reduction of the double chin and redefining ... can cause a person to look much older and heavier causing the person distress ...
(Date:6/29/2015)... New York, NY (PRWEB) , ... June 29, 2015 , ... ... of Radiation Oncology, Care to Care. , Dr. Faber will lead the Radiation Oncology ... complexities of treatment through the use of Care to Care’s proprietary evidence based criteria. ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 2Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 3Health News:Mount Sinai Scientists Develop New Approach for More Accurate and Comprehensive Whole Genome Assembly, Variant Discovery and Interpretation 4Health News:Overdose Death Rates Decreased in Florida as of 2015 2Health News:Overdose Death Rates Decreased in Florida as of 2015 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 2Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 3Health News:State and Local Governments Are Slow to Adopt Next Generation 9-1-1 Systems, According to New Research from General Dynamics Information Technology 4Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 2Health News:Care to Care, LLC Appoints a New Section Chief of Radiation Oncology 3
... a,non-profit organization focused on prevention and recovery from Autism,ADHD ... organization,through three major steps:, 1. Jenny McCarthy, Deirdre ... Ms. McCarthy is a best-selling author, actress, activist, ... latest book, Louder than Words,profiled her own son,s journey ...
... Product That Gives Consumers an All-Natural Cottage Cheese Containing ... ... Beginning in early June, a new,cottage cheese with more healthy ... with Pro-Active,Nutrients. The first to offer this nutrition and health ...
... Management Society of America to Sponsor MEP Workshop at Annual ... ... May 22 The Population Health Impact,Institute (PHII), a non-profit 501(c)(3) ... draft Methods Evaluation,Process(TM) (MEP(TM)) Accreditation Standards. The comment period ends on,July ...
... An experimental drug has blocked the progression of ... form of the disease, new research shows. , The ... called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate ... off by the cancer process. , The study, conducted ...
... that in the dog-eat-dog, look-out-for-No. 1, highly competitive business ... to succeed as an entrepreneur. That statement may sound ... A team led by a University of Missouri researcher ... and women decide to pursue entrepreneurship as a viable ...
... 22 Parks Associates and CEA(R) today,announced ... free pre-show session,at CONNECTIONS(TM) on June 24. ... coalition of the finest healthcare and technology,companies ... quality of,personal healthcare by establishing a system ...
Cached Medicine News:Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 2Health News:Generation Rescue to Target Treatment-Based Research for Autism and ADHD - Jenny McCarthy, Deirdre Imus, and Katie Wright Join Board 3Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 2Health News:New Friendship Cottage Cheese Boosts Digestive & Bone Health 3Health News:Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period 2Health News:Experimental agent blocks prostate cancer in animal study 2Health News:Taking care of business shouldn't be just for men 2Health News:Continua Health Alliance Provides Insight Into Next Generation of Digital Health at CONNECTIONS(TM) 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: